Personas / Equipo Humano

Alicia Castañeda Heredia

Buscador de publicaciones

Publicaciones

  • Kuhlen M, Roganivic J, Naviglio S, Baecklund F, Bello R, Ben-Ami T, Bergamaschi L, Bilic E, Bien E, Brito MJ, Castañeda-Heredia A, Cesen Mazic M, Dos Reis Farinha NJ, Jovanovska A, de Krijger R, Debora de Pasquale M, Elisei R, Grau Bolado G, Guillén G, Haissaguerre M, Hartl D, Huerta-Aragonés J, Krawczyk MA, Lamartina L, Leite F, Leite V, López Almaraz R, Manevska N, Mansuy L, Miele E, Naderi EH, Nordmann Winther T, Petit IO, Özön ZA, Podda MG, Pourtsidis A, Reguerre Y, Sandström M, Schneider DT, Ekinci S, Suput Omladic J, Sztangierska B, Verite C, Waespe N, Wong KH, Yalcin B, Abele M, Bisogno G, Orbach D, Brecht IB, Virgone C and Redlich A.

    Who leads, who treats, what dose? European paediatric differentiated thyroid carcinoma practice-an European Cooperative Study Group for Paediatric Rare Tumours survey.

    EUROPEAN JOURNAL OF ENDOCRINOLOGY . 194(6): 756-768.

    [doi:10.1093/ejendo/lvag091]

  • Santa-María López V, Felip-Badia A, Marina Caballero Bellón, Sanchez-Sierra N, Castañeda-Heredia A, Garraus-Oneca M, Gorostegui M, Simão-Rafael M, Muñoz JP, Pérez-Somarriba M, Mañe S, Planells MC, Pérez-Jaume S and Mora J.

    Prognostic Impact of Treatment Modalities, Including Targeted Compartmental Radio-Immunotherapy, in a Cohort of Neuroblastoma Patients With CNS Metastases at Relapse

    PEDIATRIC BLOOD & CANCER . 73(4): .

    [doi:10.1002/1545-5017.70105]

  • Ortega-Bertran S, Fernández-Rodríguez J, Magallón-Lorenz M, Creus-Bachiller E, Uriarte-Arrazola I, Mazuelas H, Garraus-Oneca M, Carrió M, Gel B, Rovira-Zurriaga C, Alvarez M, Villanueva A, Castañeda-Heredia A, Salvador-Hernandez H, Serra E and Lázaro C.

    Personalized medicine strategy for MPNSTs: using precision oncology on PDOX models to inform tumor boards

    Journal of Translational Medicine . 24(1): .

    [doi:10.1186/s12967-026-07751-9]

  • Carceller, F, Bautista, F, Van Tinteren, H, Castañeda-Heredia A, Surun, A, Wasti, A, Revon-Rivière, G, Bergamaschi, L, Cortés, M, Hladun-Alvaro, R, Jiménez, I, Giraudi, C, Millen, G, Campbell-Hewson, Q, Juan-Ribelles, A, Van der Lugt, J, Amoroso, L, Bertorello, N, Hargrave, D, Vega-Piris, L, Fagioli, F, Haupt, R, Zwaan, CM, Cañete, A, Morlandj, B, Cerauloi, A, Casanova, M, Verschuur, A, André, N, Aerts, I, Doz, F, Pearson, ADJ, Marshall, LV, Vassal, G, Kearnsj, P, Geoerger, B and Moreno, L.

    Prognostic factors of early mortality in children and adolescents with relapsed/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: An ITCC study

    EUROPEAN JOURNAL OF CANCER . 227: .

    [doi:10.1016/j.ejca.2025.115627]

  • Sentís I, Melero JL, Cebrià A, Grzelak M, Soto M, Michel A, Rovira Q, Rodriguez-Hernandez CJ, Caratù G, Urpi A, Sauvage C, Mendizabal-Sasieta A, Maspero D, Lavarino C, Pascual-Reguant A, Castañeda-Heredia A, Muñoz Perez JP, Mora J, Harari A, Nieto JC, Avgustinova A and Heyn H.

    Spatiotemporal T-cell tracking for personalized T-cell receptor T-cell therapy designs in childhood cancer.

    ANNALS OF ONCOLOGY . 36(9): 1096-1106.

    [doi:10.1016/j.annonc.2025.05.530]

  • Cristina Larrosa Espinosa, Mico S, Ramos M, Pérez-Jaume S, Sánchez M, Castañeda-Heredia A, Garraus-Oneca M and Mora J.

    Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomes

    PEDIATRIC BLOOD & CANCER . 71(10): . Nº de citas: 1

    [doi:10.1002/pbc.31221]

  • Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK.

    Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects

    Frontiers in Oncology . 14: 1380917-1380917.

    [doi:10.3389/fonc.2024.1380917]

  • Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.

    Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy

    Cancers . 16(9): . Nº de citas: 3

    [doi:10.3390/cancers16091735]

  • Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J.

    Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes

    Cancers . 15(19): . Nº de citas: 22

    [doi:10.3390/cancers15194837]

  • Gomez-Gonzalez S, Llano-Viles J, Garcia-López M, Garrido- García A, Suñol M, Lemos I, Pérez-Jaume S, Salvador-Marcos N, Gene-Olaciregui N, Galán RA, Santa-María López V, Pérez-Somarriba M, Castañeda-Heredia A, Hinojosa J, Winter U, Moreira FB, Lubieniecki F, Vazquez V, Mora J, Cruz-Martínez O, Morales-La Madrid A, Perera A and Lavarino C.

    EpiGe: A machine-learning strategy for rapid classification of medulloblastoma using PCR-based methyl-genotyping

    iScience . 26(9): 107598-107598. Nº de citas: 1

    [doi:10.1016/j.isci.2023.107598]